Protective effects on isolated hearts with developing infarction: slow channel blockade by diltiazem versus beta-adrenoceptor antagonism by metoprolol.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D002304:Cardiac Pacing, Artificial; D003250:Constriction; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000201:enzymology / Q000209:etiology / Q000378:metabolism; D004110:Diltiazem / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010101:Oxygen Consumption / Q000187:drug effects; D011412:Propanolamines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains
D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D002121:Calcium Channel Blockers; D011412:Propanolamines; D004110:Diltiazem; D008790:Metoprolol